Various adverse cutaneous reactions to anti-TNF-α monoclonal antibody have been reported. In clinical studies with infliximab (Remicade®) adverse drug reactions were most frequently reported in the respiratory system and in the skin and appendages. We describe here 6 patients receiving anti-TNF-α therapy (infliximab) for Crohn’s disease or rheumatoid arthritis who consulted our out-patient department for adverse cutaneous reactions between November 1999 and February 2002. The following diagnoses were made: leukocytoclastic vasculitis, lichenoid drug reaction, perniosis-like eruption (2 patients), superficial granuloma annulare and acute folliculitis.